Observational studyThe journal of headache and pain2025
Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study.
Observational study in The journal of headache and pain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention.The journal of headache and pain · 2025Trial
- Efficacy, Safety, and Tolerability of Atogepant in Migraine Patients from the UAE.Neurology and therapy · 2026Article
- Prescriber adherence to treatment guidelines for monoclonal antibodies against Calcitonin Gene-Related Peptide in migraine prophylaxis - a register-based cohort study.The journal of headache and pain · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWhile erenumab and fremanezumab are effective treatments for migraine prevention, it is unclear whether patients who experience adverse events related to erenumab can tolerate fremanezumab. This study evaluated the tolerability of switching from erenumab to fremanezumab in patients with chronic migraine who experienced adverse events on erenumab.
methodsData was obtained from adult patients with chronic migraine who failed erenumab treatment due to lack of tolerability and subsequently received at least three months of treatment with fremanezumab after discontinuing erenumab. Adverse events were recorded before and after the switch.
resultsIn total, 94 patients were enrolled, with a median age of 50 years. Hereof, 29 (31%) participants experienced treatment-emergent adverse events during the study period after switching from erenumab to fremanezumab. The most prevalent adverse event on erenumab before switching was constipation (n = 74, 79%), which reduced to only 12% (n = 9) of patients who switched to fremanezumab. There was no treatment discontinuation after switching to fremanezumab during the three-months study period.
conclusionSwitching treatment from erenumab to fremanezumab due to adverse events is well-tolerated in patients with chronic migraine. This findings suggests a viable option to switch between treatments. Further studies are needed to assess the efficacy of switching between these treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.